Hepatocellular carcinoma or HCC is the most commonly observed form of liver cancer and the fourth leading cause of ...

Infinity Bio, a leader in antibody reactome profiling, announces the launch of HuSIGHT-Total™, the world’s most comprehensive ...

Infinity Bio, a leader in antibody reactome profiling, announces the launch of HuSIGHT-Totaltm, the world's most comprehensive autoantibody analysis service. This new offering provides an unparalleled ...

Significant associations were found between certain autoantibodies and neuropsychiatric manifestations of SLE.

Tremfya is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

In what could be a preview of an even greater disease burden for those workers in the artificial stone benchtop industry, ...

The study, which will serve “as a guide for rapid diagnosis”, provides valuable information for the medical community, in ...

J&J seeks EU approval of nipocalimab to treat people living with generalised myasthenia gravis: Beerse, Belgium Saturday, September 14, 2024, 13:30 Hrs [IST] Janssen-Cilag Interna ...

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Cabaletta Bio (CABA – Research Report), with a ...

Johnson & Johnson has announced that the US FDA has approved TREMFYA for the treatment of active ulcerative colitis (UC).